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ZBTB32 restrains antibody 
responses to murine 
cytomegalovirus infections, but not 
other repetitive challenges
Arijita Jash1, You W. Zhou  2,3, Diana K. Gerardo4, Tyler J. Ripperger4,  
Bijal A. Parikh  1, Sytse Piersma  2,3, Deepa R. Jamwal5, Pawel R. Kiela5, 
Adrianus C. M. Boon2,6,7, Wayne M. Yokoyama  2,3, Chyi S. Hsieh2,3 & Deepta Bhattacharya1,4*
ZBTB32 is a transcription factor that is highly expressed by a subset of memory B cells and restrains the 
magnitude and duration of recall responses against hapten-protein conjugates. To define physiological 
contexts in which ZBTB32 acts, we assessed responses by Zbtb32−/− mice or bone marrow chimeras 
against a panel of chronic and acute challenges. Mixed bone marrow chimeras were established in 
which all B cells were derived from either Zbtb32−/− mice or control littermates. Chronic infection of 
Zbtb32−/− chimeras with murine cytomegalovirus led to nearly 20-fold higher antigen-specific IgG2b 
levels relative to controls by week 9 post-infection, despite similar viral loads. In contrast, IgA responses 
and specificities in the intestine, where memory B cells are repeatedly stimulated by commensal 
bacteria, were similar between Zbtb32−/− mice and control littermates. Finally, an infection and 
heterologous booster vaccination model revealed no role for ZBTB32 in restraining primary or recall 
antibody responses against influenza viruses. Thus, ZBTB32 does not limit recall responses to a number 
of physiological acute challenges, but does restrict antibody levels during chronic viral infections that 
periodically engage memory B cells. This restriction might selectively prevent recall responses against 
chronic infections from progressively overwhelming other antibody specificities.
Immunological memory is a hallmark characteristic of the adaptive immune system. Upon clearance of infec-
tions or vaccines, a pool of antigen-specific lymphocytes remains, poised to rapidly respond to immunogen 
re-exposure. When these memory lymphocytes are subsequently engaged by their cognate immunogens, the 
resulting recall responses are typically of greater magnitude and rapidity than the antecedent primary reaction. A 
number of studies have identified gene expression differences between naïve and memory lymphocyte subsets1–6. 
However, the crucial genetic programs that functionally distinguish naïve and memory lymphocytes are not fully 
known, especially within the B cell lineage7.
The transcription factor ZBTB32 is highly expressed by a subset of mouse and human memory B cells, 
but not by naïve B cells6,8–11. We recently demonstrated that in the absence of ZBTB32, recall responses to T 
cell-dependent model antigens were much more rapid and durable than those mounted by control memory B 
cells8. In contrast, primary responses were unaffected by ZBTB32-deficiency against these hapten-protein conju-
gates. ZBTB32-deficient recall responses were characterized by the rapid production of antibody-secreting cells in 
the spleen, and then durable maintenance of plasma cells in the bone marrow8. ZBTB32 itself was not detectably 
expressed in these secondary plasma cells8. Instead, the direct effects of this transcription factor likely occurred 
during memory B cell activation, perhaps by limiting MHCII expression, antigen processing, and as a result, T 
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cell help8,12. In the absence of ZBTB32, the resultant secondary plasma cells display enhanced transcriptional 
signatures of mitochondrial function8, which is critical for long-term plasma cell survival13,14.
Left unaddressed by our previous work was an etiological reason for having a specific negative regulator of 
memory B cell recall responses and the physiological consequences of lacking this factor. We first considered the 
possibility that ZBTB32 acts as a tumor suppressor of multiple myeloma, a plasma cell malignancy. Consistent 
with the possibility that ZBTB32 might play a role in malignancies, its expression distinguishes subtypes of dif-
fuse large B cell lymphomas15. However, an examination of multiple myeloma sequencing studies and the Broad 
Institute Multiple Myeloma Genomics Portal (http://portals.broadinstitute.org/mmgp/home) revealed no evi-
dence of recurrent Zbtb32 mutations16. We next considered the possibility that inherited Zbtb32 mutations may 
predispose towards autoimmunity. Again, a survey of genome-wide association study databases and primary 
literature revealed no connections between Zbtb32 and autoimmune disorders17–26. Moreover, we observed no 
signs of spontaneous autoimmunity in Zbtb32−/− animals. Finally, we reasoned that ZBTB32 might maintain 
the breadth of humoral immunity by preventing the unnecessary accumulation of secondary plasma cells. Most 
individuals bear 8–12 chronic viral infections that can become periodically reactivated under appropriate con-
ditions27. This reactivation triggers memory recall responses, an inflation of oligoclonal specificities, and loss of 
lymphocyte diversity that becomes most pronounced with age28. Cytomegalovirus is perhaps the best studied 
pathogen in which each of these effects is observed, at least for T cells29,30. It is possible that ZBTB32 prevents or 
slows such effects for B cells. Reciprocally, if ZBTB32-deficiency prevents secondary plasma cells from dying, each 
recall response might leave behind an outsized footprint and competitively inhibit both pre-existing and subse-
quent plasma cells from accessing limited survival factors or ‘niches’31. We reasoned that chronic infections would 
be most likely to reveal such effects of ZBTB32 deficiency on memory B cell activation and plasma cell survival.
Results
ZBTB32 restrains MCMV-specific antibody responses after infection. ZBTB32 is highly expressed 
by isotype-switched memory B cells, both in mice and humans6,8,9,11. In mice, the highest levels of ZBTB32 are 
restricted to the CD80+ subset of memory B cells, which rapidly differentiate into plasma cells but lack the ability 
to initiate germinal center reactions6. Our studies using knockout mice demonstrated that ZBTB32 limits the 
rapidity and duration of memory B cell responses against hapten-protein conjugates8. Yet the physiological con-
texts in which this negative regulatory pathway is engaged remain unclear.
Murine cytomegalovirus (MCMV) infections trigger a slow but progressive inflation of antigen-specific IgG 
over time32. This inflation is not associated with increases in MCMV-specific IgM from naïve B cells, antibody 
avidity, or persistent germinal center reactions, implying the reactivation of isotype-switched memory B cells as 
MCMV intermittently exits latency32. As MCMV initiates a lifelong infection33, this process might continue for 
the lifespan of the host as the virus periodically becomes reactivated. We hypothesized that ZBTB32 limits the 
magnitude of this antibody inflation caused by MCMV infection.
ZBTB32 has been shown to promote natural killer (NK) cell proliferation after MCMV infection34, and NK 
cells are essential for control of MCMV infection35–37, which would confound the study of ZBTB32 effects on B 
cells in genetically deficient animals. We therefore established mixed chimeras in which CD45.2+ bone marrow 
cells from Zbtb32−/− or Zbtb32+/+ controls were mixed with equal numbers of B cell-deficient μMT bone marrow 
cells and transplanted into irradiated CD45.1+ recipients (Fig. 1A)38. After reconstitution, B cells were exclusively 
CD45.2+, and comparable levels of B cells were observed between Zbtb32+/+ and Zbtb32−/− chimeras (Fig. 1B). 
This system ensures that while all B cells in the experimental group are derived from Zbtb32−/− donors, half of 
all other hematopoietic and immune lineages, including NK cells, are derived from μMT mice and functionally 
normal within the same recipients (Fig. 1A).
Chimeras were challenged with 105 PFU of MCMV-WT1, a subclone of the Smith strain of MCMV39, and 
antigen-specific antibody titers were measured at 1 week post-infection and every 2 weeks afterwards. IgM titers 
were slightly elevated in Zbtb32−/− chimeras at week 1 (Fig. 1C, top panel). After this point, MCMV-specific IgM 
gradually declined irrespective of genotype and eventually fell below the limit of detection after week 5 (Fig. 1C, 
top panel). At weeks 1–3 post-infection, MCMV-specific IgG2b levels were similar in Zbtb32−/− chimeras relative 
to Zbtb32+/+ controls (Fig. 1C, middle panel). Following a decline at week 5, presumably the point at which acute 
infection was resolved, MCMV-specific IgG2b levels rapidly rose in Zbtb32−/− chimeras until week 9, reaching 
nearly 20-fold higher titers than in control chimeras (Fig. 1C, middle panel).
Between weeks 9 and 11 post-infection, MCMV-specific IgG2b levels plateaued in Zbtb32−/− chimeras, 
whereas antigen-specific IgG2b rose in wild-type chimeras (Fig. 1C, middle panel). Yet despite this late increase, 
MCMV-specific antibodies from wild-type chimeras still remained below the levels observed in Zbtb32−/− chi-
meras (Fig. 1C, middle panel). Similarly, antigen-specific IgG2c levels in Zbtb32−/− chimeras rose to 3-fold higher 
levels than controls at week 3 post-infection, and then were maintained at modestly elevated levels through week 
11 (Fig. 1C, bottom panel). After this point, antibody titers declined to the levels observed in wild-type chimeras 
(Fig. 1C, bottom panel). These data demonstrate that ZBTB32 restricts antibody responses to MCMV, particularly 
during the period after the initial acute response.
Although half of all non B-lineage cells in our chimeras were functionally wild-type, ZBTB32 has been impli-
cated in both NK and T cell function34,40–43. Thus, we were concerned that MCMV viral levels might have differed 
between our control and experimental groups since half of all T and NK cells were ZBTB32-deficient. Elevated 
MCMV levels could in turn inflate antigen load and antibody responses. To test this possibility, we assessed MCMV 
levels through quantitative PCR. Serum levels of MCMV DNA were similar between ZBTB32-deficient and –suf-
ficient chimeras at week 1 post-infection (Fig. 1D), arguing against differences in viral load. At later timepoints, 
MCMV was undetectable in the serum (not depicted), consistent with the establishment of latency. Coupled with 
our observation that initial IgG titers were similar between groups, our data demonstrate that ZBTB32-deficient 
chimeras show exaggerated MCMV-specific antibody levels despite similar viral loads as in controls.
3Scientific RepoRtS |         (2019) 9:15257  | https://doi.org/10.1038/s41598-019-51860-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
Initial activation stimulus, rather than isotype, dictates memory B cell dependence on ZBTB32. 
In the absence of ZBTB32, IgG2b responses to MCMV were more dramatically affected than were IgM or IgG2c 
(Fig. 1C). There are several potential mechanisms for this observation. First, it is possible that only certain iso-
types of memory B cells depend on ZBTB32 to restrain recall responses. Second, it may be that the initial innate 
Figure 1. ZBTB32 restrains MCMV-specific antibody responses after infection. (A) Schematic of bone marrow 
chimeras and MCMV infections. Equal numbers of bone marrow cells from Zbtb32−/− or Zbtb32+/+ donors and 
μMT donors were mixed and transplanted into irradiated wild-type IgHa recipients. Chimeras were infected 
with MCMV-Smith and antigen-specific antibodies were followed over time. (B) Representative flow cytometry 
plots and quantification of peripheral blood B cell reconstitution in Zbtb32+/+ or Zbtb32−/− bone marrow 
chimeras 8 weeks post-transplantaton. No significant differences were observed by students’ 2-tailed t-tests. 
(C) ELISA measurements of MCMV-specific IgM, IgG2b, and IgG2c over time. Mean values ± SEM are shown. 
*p < 0.05; **p < 0.005; ***p < 0.0005 by 2-way ANOVA and post-hoc Sidak’s multiple correction test. Data are 
cumulative of two independent experiments. (D) Serum MCMV viral titers as measured by quantitative RT-
PCR. Threshold cycle (Ct) values were calculated at different serum dilutions at 1 week post-infection. Dashed 
line represents the value from uninfected naïve mice and the lower limit of detection. Mean values ± SEM are 
shown. No significant differences were observed by 2-way ANOVA and post-hoc Sidak’s multiple correction.
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activation stimuli dictate ZBTB32 dependence, irrespective of isotype. The latter mechanism would be similar to 
our findings on the related transcription factor, ZBTB2044. In these earlier studies, we determined that the adju-
vant, rather than antibody isotype, determines the dependence of plasma cell survival on ZBTB2044. For ZBTB32, 
our previous work relied exclusively on alum-adjuvanted immunizations with NP-CGG8. We therefore immu-
nized Zbtb32+/+ or Zbtb32−/− mice with NP-CGG adjuvanted with monophosphoryl lipid A, a TLR4 ligand, 
and trehalose dicorynomycolate, a TLR2 ligand derived from Mycobacterium tuberculosis, in an oil-in-water 
emulsion. This formulation is similar to Ribi adjuvant, for which in contrast to alum, the bulk of long-term 
antibody production is TLR dependent45. At 8–10 weeks post-immunization, splenocytes were adoptively trans-
ferred into naïve IgHa recipients (Fig. 2A). These mice were challenged with soluble NP-CGG to selectively 
recall donor memory B cells, and IgG1 responses were measured 2 weeks later. No differences in NP-specific 
IgG1b were observed, irrespective of genotype (Fig. 2B). These data contrast with experiments when memory B 
cells were transferred after alum-adjuvanted immunization, where Zbtb32−/− donor cells mounted a markedly 
higher and persistent IgG1 recall response than did controls beginning at day 3 post-immunization8. Thus, we 
conclude that the initial activation stimulus in the primary response that gives rise to memory B cells dictates 
ZBTB32-dependence, whereas the antibody isotype does not.
ZBTB32-deficiency minimally impacts IgA responses to intestinal bacteria. ZBTB32 is even more 
highly expressed by memory B cells in the intestine than those in the spleen10. A substantial fraction of IgA+ 
memory B cells in the gut respond to intestinal bacteria repeatedly over the course of a lifetime46–49, generating 
both short- and long-lived plasma cells50. The persistence of IgA plasma cells of a given specificity is limited in 
part by competition with other more recently formed antibody-secreting cells directed against other antigens51. 
We thus reasoned that ZBTB32, by restricting the persistence of secondary plasma cells, might promote IgA 
diversity in the gut, and thereby promote microbial homeostasis. To begin to test this possibility, we first exam-
ined serum IgA levels, which can grossly reflect differences in microbial content52. Serum IgA levels trended 
slightly lower in Zbtb32−/− animals relative to controls (Fig. 3A), but this did not reach statistical significance 
(2-way ANOVA, p = 0.37 at a serum dilution of 1:3200, powered to reveal 2.5-fold differences). To more precisely 
quantify bacterial composition, we performed 16S ribosomal RNA gene sequencing of fecal matter. Microbial 
content between Zbtb32−/− and Zbtb32+/− littermates was similar both at the operational taxonomic unit (OTU) 
(p = 0.211) and family level (p = 0.213) as determined by permutation-based ANOVA (Fig. 3B).
Having confirmed similar intestinal microbial content between Zbtb32 genotypes, we next defined the specif-
icities of IgA responses using Bacteria FACS. In this approach, IgA-bound bacteria from fecal matter are purified 
by fluorescence-activated cell sorting and subjected to 16S ribosomal RNA gene sequencing (Fig. 3C)49,53,54. The 
sequencing information allows for assignment of operational taxonomic units (OTUs) and an estimation of the 
diversity of bacteria recognized by IgA49. 16S sequencing of these IgA-bound bacteria revealed similar overall IgA 
Figure 2. Ribi-adjuvanted immunization yields ZBTB32-independent recall responses. (A) Schematic of 
primary immunization, adoptive transfer, and secondary immunizations. (B) ELISA measurement of memory B 
cell responses. Zbtb32+/+ and Zbtb32−/− mice were immunized Ribi-adjuvanted NP-CGG and 8–10 weeks later 
splenocytes were transferred to naïve IgHa recipients. One day later, recipients were immunized intravenously 
with soluble NP-CGG. Donor IgG1b NP-specific antibodies were quantified by ELISA. Each data point 
represents an individual mouse. Error bars depict geometric means ± 95% confidence interval. Differences were 
statistically insignificant as determined by Mann–Whitney test (p = 0.41).
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Figure 3. ZBTB32-deficiency minimally impacts IgA responses to intestinal bacteria. (A) Serum IgA levels in 
8 week-old Zbtb32−/− or Zbtb32+/+ mice, measured by ELISA. Mean values ± SEM are shown. No significant 
differences were observed by 2-way ANOVA followed by post-hoc Sidak’s multiple comparisons test. (B) 
Bacterial content in fecal pellets of Zbtb32−/− and Zbtb32+/− littermates as revealed by 16S rDNA sequencing. 
Data shown are family level taxa for individual mice. No statistically-significant differences between genotypes 
were observed at the family or OTU level by permutation ANOVA. (C) Representative flow cytometric plot 
of IgA-bound bacteria in fecal pellets. Bacteria were gated as DAPI+ and isotype control negative events 
and assessed for IgA and IgG staining. Data are representative of two independent experiments comparing 
littermates (Zbtb32−/−, n = 5; Zbtb32+/−, n = 4). (D) Volcano plot showing the IgA-enrichment (log2 (% of OTU 
in IgA+/IgA−) vs t-test p-value. As ratios are very susceptible to small denominators, data are calculated using 
a filtered dataset (139 OTUs present in ≥2 samples for each genotype at >0.1% frequency). In addition, IgA 
enrichment per individual was arbitrarily capped at log2(50 or 1/50) to limit effects of small denominators. No 
OTU comparison passes FDR < 0.25. (E) IgA enrichment values for top 8 OTUs based on greatest differences 
between genotypes by p-value, and for those with largest relative abundance. Taxonomic assignments at the 
genus level for each OTU are shown if available. IgA-enrichment is calculated as per (D). (F) Rarefaction plot 
shows the average species diversity and 95% confidence limits at different sampling intervals. Unc, unclassified 
at the taxa level presented, with the best higher level assignment noted.
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specificities between Zbtb32−/− and Zbtb32+/− littermates (Fig. 3D), as assessed by the ratio of the OTU frequency 
in the IgA+ over the IgA− sorted samples (2-way ANOVA, p = 0.26). There was one Sutterella OTU which was 
decreased in the knockout (t-test, p = 0.007), but was not significant after false discovery rate (FDR) correction, 
even using a filtered dataset of 139 OTUs (Fig. 3E, left panel). The top 8 IgA-bound OTUs in either genotype also 
did not show significant changes in the IgA-bound ratio (Fig. 3E, right panel). Finally, rarefaction plots, in which 
the number of different OTUs are plotted against the sequences per sample55, did not reveal statistically significant 
changes in the alpha diversity of IgA-bound OTUs between genotypes (Fig. 3F). While additional samples might 
provide more statistical power to demonstrate subtle differences in IgA binding to select OTUs, these data suggest 
that ZBTB32-deficiency does not markedly affect the specificity or production of IgA to gut bacteria.
Previous studies on NK cells demonstrated a significant phenotype in heterozygous Zbtb32+/− mice relative 
to wild-type controls34. As our studies focused on comparisons between Zbtb32−/− and Zbtb32+/− mice, it is 
possible that we overlooked a dosage effect for ZBTB32. We therefore generated new crosses to compare bacterial 
IgA responses between Zbtb32+/− and Zbtb32+/+ littermates. We observed no differences between Zbtb32+/− and 
Zbtb32+/+ littermates in the frequency of IgA-bound bacteria (Fig. 4A). 16S sequencing of IgA-bound bacteria 
also revealed few statistically-significant differences in enriched OTUs between genotypes (Fig. 4B). Moreover, 
the overall diversity of IgA-bound OTUs was also similar between Zbtb32+/− and Zbtb32+/+ littermates (Fig. 4C). 
We thus conclude that despite some differences in individual bacterial specificities, ZBTB32-deficiency does not 
limit overall IgA target diversity in the gut.
ZBTB32 does not restrain recall responses to influenza vaccines. Primary responses to unadju-
vanted influenza vaccines are often quite weak56,57. In contrast, memory B cells are capable of mounting antibody 
responses against both influenza infections and unadjuvanted vaccinations. For example, protective responses 
against the A/California/07/2009 H1N1 influenza strain were highly correlated with pre-existing cross-reactive 
memory B cells58–61. Upon heterologous challenges, these cross-reactive memory B cells might undergo further 
affinity maturation to focus the response on the new strain, both against the variable head region and conserved 
stalk region of influenza hemagglutinin (HA)59. The duration of influenza immunity after recall challenges can in 
some cases be very durable62, but is generally short-lived when unadjuvanted vaccines are used63.
To determine if ZBTB32-deficiency extends the duration of antibody responses against influenza, we adopted 
an infection and heterologous vaccination model (Fig. 5A). Zbtb32−/− or control littermates were first infected 
with the influenza H1N1 strain A/Puerto Rico/8/1934 (A/PR8). Antibody responses were similar against recom-
binant A/PR8 hemagglutinin (HA) protein between Zbtb32+/+ and Zbtb32−/− littermates through 12 weeks 
post-infection (Fig. 5B). At this point, mice were re-challenged with H1N1 A/California/7/2009 (A/Cali) mono-
valent vaccine (Fig. 5A). Naïve mice that had not first been infected with A/PR8 mounted no detectable antibody 
responses to HA from A/Cali (Fig. 5C, left column), confirming that primary responses to this unadjuvanted 
vaccine are weak. Moreover, A/PR8-immune mice showed minimal serum antibody reactivity against A/Cali HA 
prior to vaccination (Fig. 5C, week 0). Vaccination with A/Cali did not enhance antibody responses to A/PR8 
HA (Fig. 5B, weeks 1–5). However A/PR8-immune mice mounted a robust recall response against A/Cali HA 
(Fig. 5C), presumably because of the presence of cross-reactive memory B cells. These data are consistent with 
our previous findings that long-lived plasma cells, which durably maintain antibodies in the serum, possess spe-
cificities restricted to the original strain, whereas memory B cells are considerably more diverse64. In this system, 
secondary responses to A/Cali were exceptionally durable even in wild type mice, with no measurable decline 
in antibody titers between 1–12 weeks post-vaccination (Fig. 5C). Recall responses by ZBTB32-deficient mice 
were similar to controls throughout the course of the experiment (Fig. 5C). Thus, unlike the transient responses 
elicited by hapten-protein conjugate-based booster immunizations8, antigen-specific antibody titers are already 
maintained durably after an acute influenza vaccination and ZBTB32 exerts no additional influence in restricting 
responses.
Figure 4. ZBTB32-haploinsufficiency minimally impacts IgA responses to intestinal bacteria. (A) 
Quantification of IgA-bound bacteria in fecal pellets. Bacteria were gated as DAPI+ and isotype control- events 
and assessed for IgA and IgG staining as in Fig. 3C. Lack of statistical significance was determined by students’ 
2-tailed t-test. (B) Volcano plot showing IgA-enrichment (log2 (% of OTU in IgA+/IgA−) vs t-test p-value. 
No OTU comparison passed FDR < 0.25. (C) Rarefaction plot shows the average species diversity and 95% 
confidence limits at different sampling intervals.
7Scientific RepoRtS |         (2019) 9:15257  | https://doi.org/10.1038/s41598-019-51860-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
Discussion
The adaptive immune system is exposed to nearly constant stimulation, both from new antigens as well as 
immunogens that have been seen previously. Memory lymphocytes are responsible for responding to previously 
encountered antigens, and generally mount more rapid and robust responses than their naïve precursors. In pre-
vious work using model antigens, we demonstrated that the expression of ZBTB32 is utilized by memory B cells 
to attenuate recall responses8. On one hand, the existence of such a negative regulator seems peculiar. Durable and 
robust recall responses seem to be traits that should be evolutionarily favored. On the other hand, there are pre-
sumably only a finite number of plasma cells that can be maintained31. Thus, mechanisms may exist to limit the 
numbers of long-lived plasma cells to only what is necessary for protection65. Indeed, we previously demonstrated 
that only 1 μl of passively transferred immune serum was sufficient to protect mice from an otherwise lethal dose 
of West Nile virus64. This corresponds to antibodies from only 3 antigen-specific long-lived plasma cells. Thus, 
keeping a relatively small number of antigen-specific plasma cells would maximize the potential breadth of anti-
bodies while simultaneously maintaining protective immunity.
The contexts in which memory B cells would need to engage such a negative regulatory pathway, however, 
are unclear. Influenza and malaria infections can occur repeatedly62,66, which in turn could reduce the overall 
diversity of plasma cells if factors such as ZBTB32 were not in place. Yet the frequency of these types of infections, 
even in endemic areas, are unlikely to exceed one per year66. Thus, it seems unlikely that recall responses to these 
acute infections would dramatically alter the content of pre-existing plasma cells, even in the absence of ZBTB32. 
Indeed, based on our previous work using high doses of hapten-based antigens8, we estimate that only 1000–2000 
long-lived plasma cells were generated in excess and maintained following recall responses by ZBTB32-deficient 
mice. Thus, repeated and distinct acute challenges seem unlikely to necessitate negative regulatory mechanisms 
such as ZBTB32 expression. Indeed, we observed no role for ZBTB32 in restricting antibody responses in mouse 
models of influenza infection and vaccination, nor in responses to intestinal bacteria. The mechanistic basis for 
the differences in responses to haptens, influenza viruses, and intestinal bacteria is not clear, but may involve the 
innate signals and inflammatory environment that imprint upon the memory B cell population67. In support of 
Figure 5. ZBTB32 does not restrain recall responses to influenza vaccines. (A) Schematic showing infection 
and heterologous vaccination schedule. (B) ELISA titers against recombinant hemagglutinin from A/PR8 at 
12 weeks post-primary infection (0 weeks post-rechallenge), and after heterologous A/Cali vaccination. Mean 
endpoint titers ± SEM are shown. No statistically significant differences were observed by Mann-Whitney test, 
or by 2-way ANOVA and post-hoc Sidak’s multiple comparison’s test. (C) ELISA titers against recombinant 
hemagglutinin from A/California after vaccination of naïve mice (left panel) or A/PR8-immune mice (right 
panel). Mean endpoint titers ± SEM are shown. No statistically significant differences were observed by Mann-
Whitney test, or by 2-way ANOVA and post-hoc Sidak’s multiple comparison’s test.
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this concept, memory B cells of different antibody isotypes use distinct transcription factors to form and per-
sist68. Immunoglobulin isotype-switching is linked to the particular cytokines induced by immunization- or 
infection-specific innate signals69. Such differences in innate signals during memory B cell ontogeny could in 
turn influence the persistence of secondary plasma cells following recall responses. Indeed, our previous work on 
a related BTB-POZ transcription factor, ZBTB20, revealed an adjuvant-specific requirement in mediating durable 
antibody responses44. Nonetheless, both for ZBTB20 and ZBTB32, our findings argue against a direct role for the 
antibody isotype per se. Rather, we propose that the initial activation stimuli and resultant Tfh cells determine the 
dependence on ZBTB20 and ZBTB32 for controlling antibody responses.
Responses to chronic infections may require distinct negative regulatory mechanisms to maintain home-
ostasis. CMV, in particular, has a dramatic effect on the mammalian immune system, triggering large oligo-
clonal expansions of memory lymphocytes with age29,30. There is no clear consensus on how these expansions 
impact responses to other pathogens28. Yet it seems likely that negative regulatory pathways would be important 
from keeping recall responses to chronic infections from completely overtaking both the naïve repertoire and 
pre-existing immunity. Mitigating these B cell recall responses would also be important given that antibodies are 
not especially protective against chronic infections such as CMV or norovirus70,71. Here, we found that ZBTB32 
indeed restrains antibody responses against MCMV. This effect was most pronounced after the acute infection 
phase, and was more modest at the initial and late stages of infection. Though the end effect of ZBTB32-deficiency 
may not be large for any single infection, this pathway may be particularly important given that most humans are 
chronically infected by 8–12 different viruses27. Mice exposed to more physiological insults than those in specific 
pathogen-free environments are better mimics of the human experience72, and may further reveal the importance 
of ZBTB32 in limiting recall responses.
Materials and Methods
Ethics statement. All procedures in this study were specifically approved and carried out in accordance with 
the guidelines set forth by the Institutional Animal Care and Use Committee at Washington University (approval 
numbers 20160259 and 20160002) and the University of Arizona (approval number 17–266). Euthanasia was 
performed by administering carbon dioxide at 1.5 L/minute into a 7 L chamber until 1 minute after respiration 
ceased. After this point, cervical dislocation was performed to ensure death.
Bone marrow chimeras and MCMV infection. Bone marrow cells harvested from Zbtb32+/+ and 
Zbtb32−/− mice between 8–10 weeks of age were mixed with that from μMT mice at a 1:1 ratio and injected 
intravenously into 800-cGy-irradiated CD45.1 recipients. After 8 weeks, peripheral blood was sampled from the 
tail vein to confirm reconstitution. The recipients were then infected intraperitoneally (i.p) with 1 × 105 PFU of 
MCMV-WT1, a subclone of the Smith strain of MCMV39, amplified in salivary glands, and mice were bled at the 
indicated time points to assess MCMV-specific IgM, IgG2c and IgG2b in the serum. ELISA plates were coated 
overnight at 4 °C with 1 × 103 PFU/ml of tissue-culture propagated, plaque-purified wild type MCMV in bicar-
bonate coating buffer (0.1 M sodium bicarbonate and 0.02% sodium azide at pH 9.6). Plates were washed with 
wash buffer (PBS containing 0.05% Tween 20) and after blocking 1 hr with PBS supplemented with 2% BSA and 
0.05% Tween 20 at 37 °C, serially diluted serum samples were added and incubated for 1 h at room temperature. 
Technical duplicates were performed for every serum sample. Plates were washed with PBS with 0.05% Tween 
20 and incubated with 1 µg/ml biotinylated antiIgM, anti-IgG2c or anti-IgG2b for 1 hr followed by streptavidin 
conjugated horseradish peroxidase (HRP) for 45 min. Peroxidase activity was detected by tetramethylbenzidine 
(Dako) substrate and the reaction was quenched with 2 N H2SO4 and optical densities were quantified at 450 nm. 
The endpoint titer of each sample was determined using Prism software (GraphPad Software) from a one phase 
exponential decay curve defined as the dilution that generates an OD450 value of the background plus 3 SD.
Immunization and adoptive transfer for recall responses. Zbtb32+/+ and Zbtb32−/− mice 8–10 weeks 
of age were immunized intraperitoneally (i.p.) with a single dose of 100 μg NP-CGG (hapten protein ratio: 15–22; 
Biosearch Technologies) adjuvanted with 100 μl Sigma Adjuvant System (Ribi). Spleens were harvested 8–10 
weeks post immunization and single cell suspensions of splenocytes were subjected to gradient centrifugation 
using Histopaque 119 (Sigma-Aldrich) for 10 min at 2000 × g to remove non-cellular debris. Interface cells were 
then collected and red blood cells were lysed by resuspending in buffer containing 0.15 M NH4Cl, 10 mM KHCO3, 
0.1 mM EDTA, pH 7.2. Cells were washed twice with PBS and 10% of the cells were retained for flow cytometric 
analysis. The remaining splenocytes were adoptively transferred into non-irradiated B6.CgIghaThy1aGpi1a (IgHa) 
recipient mice (Jackson Labs). A recall response was then elicited in recipient mice 24 hours later by intravenous 
administration of 50 μg of soluble unadjuvanted NP-CGG.
Serological analysis for recall responses. ELISA plates were coated overnight at 4 °C with 5 µg/ml of 
NP16bovine serum albumin (BSA) in bicarbonate coating buffer (0.1 M sodium bicarbonate and 0.02% sodium 
azide at pH 9.6). Plates were washed with wash buffer (PBS containing 0.05% Tween 20) and after blocking 1 hr 
with blocking buffer (PBS supplemented with 2% BSA and 0.05% Tween 20) at 37 °C, serially diluted serum 
samples were added and incubated for 1 h at room temperature. Technical duplicates were performed for every 
serum sample. Plates were washed with PBS with 0.05% Tween 20 and incubated with 1 µg/ml biotinylated 
antiIgG1b (B682, BD Biosciences) for 1 hr followed by streptavidin conjugated horseradish peroxidase for 45 min. 
Peroxidase activity was detected by tetramethylbenzidine substrate (Dako) and the reaction was quenched with 
2 N H2SO4 and optical densities were quantified at 450 nm. The endpoint titer of each sample was determined 
using Prism software (GraphPad Software) from a one phase exponential decay curve defined as the dilution that 
generates an OD450 value of the background plus 3 standard deviations.
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MCMV quantification by qPCR. SYBR green-based real-time qPCR was performed to measure viral 
load in the serum. Briefly 10ul of serum was diluted in PBS to a final volume of 50 µl and heated at 95 C for 
3 min and cooled rapidly on ice for 3 to 5 mins. 2 ul of serum was serially diluted and used to perform qRT-PCR 
using primers MCMV-IE1 Forward: 5′-AGCCACCAACATTGACCACGCAC-3′ and MCMV-IE1 Reverse: 
5′-GCCCCAACCAGGACACACAACTC-3′73.
Influenza infection, vaccination, and assessment of antibody titers. Zbtb32+/+ and Zbtb32−/− 
mice between 8–10 weeks of age were infected intranasally with 0.01 × LD50 A/Puerto Rico/8/1934 virus and 
were re-challenged with 50 μl H1N1/A/California/7/2009 subunit vaccine (Novartis) by intramuscular injection 
12 weeks post-infection. Coding sequences for HA from A/PR8 and A/California/7/2009 were cloned into pEF1α 
myc-His B (Invitrogen) and engineered to contain Y98F mutations as previously described74. HEK293T cells were 
transfected with these constructs in 10 cm2 dishes using FuGene HD (Promega) and supernatants collected every 
24 hours from days 2–6. Recombinant HA was purified over Ni-NTA columns (GE Health Sciences) according 
to manufacturer’s instructions. ELISA plates were coated overnight at 4 °C with 50 µg/ml of purified PR8-HA or 
Cal-HA protein in bicarbonate coating buffer (0.1 M sodium bicarbonate and 0.02% sodium azide at pH 9.6). 
ELISAs were performed as above, except with 1 µg/ml of horse radish peroxidase (HRP) conjugated anti-IgG was 
used to detect HA-specific antibodies irrespective of IgG isotype.
Bacteria FACS. Stool samples were collected from 8 week old Zbtb32−/− and Zbtb32+/− control littermates. 
Samples were resuspended in sterile PBS by vortexing and treated with N-Acetyl-L-cysteine (Sigma) to disrupt the 
mucus network. Homogenized samples were passed through a 70 μm nylon filter and stained with DAPI (Sigma), 
anti-mouse IgA DyLight 650 (Abcam ab97014), anti-mouse IgG phycoerythrin (Jackson ImmunoResearch 115-
115-164), and Goat IgG FITC Isotype control (Abcam ab37374). Samples were sorted on a BD FACS Aria IIu for 
IgA bound bacteria.
16S rDNA was amplified using the standard protocol from Caporaso et al.75. High throughput sequencing 
was performed on the Illumina Miseq platform. Assignment of bacterial OTUs from 16S sequences was accom-
plished using UParse OTU clustering algorithm and taxonomy assigned via QIIME using the uclust method with 
greenegenes database 13.876,77. Further analysis of 16S sequencing was done on R statistical computing platform 
with the use of the Vegan package (https://cran.r-project.org/web/packages/vegan/vegan.pdf).
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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